Bonnie Gillis

Articles

Chemotherapy Alone With No Radiation Superior for Limited-Stage Hodgkin Lymphoma

March 20th 2012

It may be possible to forgo radiation in previously untreated patients with limited-stage Hodgkin lymphoma.

Investigational Treatments for Multiple Myeloma

March 5th 2012

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

FISH Testing Guides Treatment of CLL: New Drugs on Horizon

January 12th 2012

FISH testing for genetic abnormalities is the key to appropriate treatment selection for patients with CLL.

Using Molecular Markers in AML for Prediction, Treatment, and Monitoring

January 5th 2012

Several molecular markers for AML are now used at top-tier cancer centers for prediction, treatment selection, and monitoring response.

Update on Bone Disease in Multiple Myeloma

December 19th 2011

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Ibandronate and Radiotherapy Provide Equivalent Pain Relief in Metastatic Prostate Cancer That Has Metastasized to the Bone

December 16th 2011

A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.

Adjuvant Zoledronic Acid May Improve Disease-Free Survival for Postmenopausal Women With Breast Cancer

December 15th 2011

A subanalysis of the AZURE study found that postmenopausal women had a disease-free survival advantage from the addition of zoledronic acid to their therapy.

Maintenance Therapy With Bevacizumab/Pemetrexed Appears Superior to Bevacizumab Alone

December 14th 2011

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

Personalized Medicine Offers Great Hope, Great Challenges

December 14th 2011

Cancer treatment is moving from a one-size-fits-all approach to personalized medicine, which means matching the right drug with the right tumor characteristics.

Some Follicular Lymphoma Patients May Benefit From Treatment Delay

December 1st 2011

Newly-diagnosed asymptomatic follicular lymphoma patients with low tumor burden can have their initial treatment delayed.

Management of Cancer-Related Anemia in 2011

November 21st 2011

Erythropoietin-stimulating agents (ESAs), once considered miracle drugs that enjoyed widespread use for cancer-related anemia, fell into disfavor in 2007.

Refining Maintenance Therapy for Multiple Myeloma

November 21st 2011

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.

Management of Adult ALL Refined

November 16th 2011

Outcomes in the treatment of acute lymphoblastic leukemia (ALL) differ in children and adults, with pediatric patients (including adolescents and young adults) having much higher cure rates than adults.

Evidence for Allogeneic Versus Autologous Stem Cell Transplant in Hematologic Malignancies

November 15th 2011

William I. Bensinger, MD, tackles the complex subject of the role of hematopoietic stem cell transplantation (HSCT), including when to transplant and whether to use allogeneic versus autologous transplant.

Novel Drugs and Combinations Promise to Improve Outcomes for Patients With Myeloma

November 14th 2011

Current treatments revolutionized multiple myeloma but combinations and novel approaches in development promise to make even greater strides in treating this disease.

Denosumab Has Lower NNT Versus Zoledronic Acid for Prevention of SREs

August 31st 2011

Fewer cancer patients need to be treated with denosumab to prevent one skeletal-related event due to bone metastases from solid tumors.

Investigational Agent Provides Hope for Patients With Myelofibrosis

August 15th 2011

Treating myelofibrosis with the investigational JAK inhibitor ruxolitinib holds promise.

Bevacizumab Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer

August 2nd 2011

Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.

Exemestane Is a New Option for Prevention of Breast Cancer in Postmenopausal Women

August 1st 2011

Postmenopausal women at risk of breast cancer got good news from the MAP.3 trial results: Exemestane reduced their risk of invasive breast cancer by 65% compared with placebo.

Novel Agent Demonstrates Activity in Heavily Pretreated Ovarian Cancer That Progressed on Pegylated Doxorubicin

August 1st 2011

A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.